NBY Novabay Pharmaceuticals Inc.
- 0 P/E
- 27.6893 P/S
- 16.8571 P/B
- -0.321 EPS
- -2,078.99% Cash ROIC
- 1.62 Cash Ratio
- 0 / 0% Dividend
- 362,598.00 Avg. Vol.
- 49.63M Shares
- 35.51M Market Cap.
NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
News Watch International - 13 hours ago
Stock Transcript - 15 hours ago
American Trade Journal - Jul 27, 2015
Smarter Analyst - Jun 5, 2015
Business Wire (press release) - Jul 30, 2015
Benzinga - Apr 30, 2015
American Trade Journal - Jul 29, 2015
Dakota Financial News - Jul 28, 2015
TheStreet.com - Jun 4, 2015
Smarter Analyst - May 15, 2015